Science & Technology

Theranostics’ RPMA technology also offers unique advantages over other existing multiplexed protein assay methods, such as antibody arrays, suspension bead arrays, mass spectrometry-based methods and tissue microarrays. It is one of the most sensitive protein detection technologies available, able to detect only a few hundred molecules or a few yoctomoles. It can analyze proteins from any source, including solid tissue, blood cells, serum, bone, vitreous and spinal fluid, with sensitivities in the fM range. Because it does not rely on sandwich-type assays and only requires a single class of antibody, it provides unmatched ability to analyze hundreds of signaling molecules at once from only a few thousand cells. The inter- and intra- assay coefficient of variation for the RPMA technology is less than 10% for clinical material, and RPMA is not hampered by antigen retrieval, a significant limitation for tissue arrays and immunohistochemical techniques.

For more information contact: technology@theranosticshealth.com